Our Pricing

Aciclovir vs Valaciclovir: Which Cold Sore Treatment Works Best?

When comparing aciclovir vs valaciclovir uk options, understanding the clinical differences between these two antiviral medications helps you choose the most effective cold sore treatment. Both are licensed by the MHRA for herpes simplex virus (HSV) suppression, but they differ significantly in dosing frequency, bioavailability, and convenience.

How Aciclovir and Valaciclovir Work Against Cold Sores

Aciclovir is a nucleoside analogue antiviral that inhibits viral DNA polymerase, preventing HSV-1 replication in infected cells [1]. When applied as a topical cream or taken orally, aciclovir reduces viral shedding and accelerates healing when started at the first sign of tingling or prodromal symptoms.

Valaciclovir is the L-valine ester prodrug of aciclovir, designed to improve oral bioavailability [2]. After absorption, valaciclovir is rapidly converted to aciclovir by hepatic first-pass metabolism, achieving three to five times higher plasma concentrations than equivalent oral aciclovir doses [2]. This enhanced bioavailability allows less frequent dosing whilst maintaining therapeutic antiviral levels.

Both medications require activation by viral thymidine kinase, meaning they selectively target infected cells and spare healthy tissue. Clinical trials demonstrate that early initiation—ideally within the first 24 hours of symptom onset—significantly improves treatment outcomes for both agents [1][3].

Aciclovir vs Valaciclovir: Dosing and Convenience

The primary clinical advantage of valaciclovir lies in its simplified dosing schedule. Standard aciclovir treatment for recurrent cold sores requires 200mg five times daily for five days, which many patients find difficult to maintain [3]. Missing doses can compromise antiviral efficacy and prolong outbreak duration.

Valaciclovir, by contrast, is typically prescribed as 2000mg twice daily for one day, or 500mg twice daily for three to five days [2][4]. This reduced dosing frequency improves treatment adherence, particularly for patients managing busy work schedules or those who prefer not to carry medication throughout the day.

Topical aciclovir cream, available from £4.49 at Cured Pharmacy, offers a non-systemic option for mild recurrent cold sores. Applied five times daily at the first sign of tingling, topical formulations may reduce healing time by approximately one day compared to untreated lesions [1]. However, systemic oral antivirals generally demonstrate superior efficacy for moderate to severe outbreaks.

When to Choose Topical vs Oral Treatment

Topical aciclovir cream suits patients experiencing infrequent, mild cold sores who prefer localised treatment without systemic absorption. Oral antivirals—whether aciclovir or valaciclovir—are recommended for patients with frequent recurrences (six or more episodes annually), severe outbreaks, or those requiring suppressive therapy to reduce transmission risk. Your UK prescriber will assess your outbreak frequency, severity, and medical history to determine the most appropriate formulation and dosing regimen during your clinical consultation.

Clinical Efficacy: Which Treatment Heals Cold Sores Faster?

Head-to-head trials comparing aciclovir vs valaciclovir show comparable clinical outcomes when both medications are taken as prescribed. A randomised controlled trial published in Antimicrobial Agents and Chemotherapy found that single-day valaciclovir therapy (2000mg twice daily) reduced median healing time to 4.0 days compared to 4.8 days with placebo—a statistically significant improvement [4].

Standard five-day oral aciclovir regimens demonstrate similar efficacy, reducing median episode duration by approximately 1.0 to 1.5 days when initiated during the prodromal phase [3]. The critical factor determining treatment success is not the choice between aciclovir and valaciclovir, but rather how quickly treatment begins after symptom onset.

For suppressive therapy in patients experiencing frequent recurrences, both medications reduce outbreak frequency by approximately 70% to 80% when taken daily [5]. Valaciclovir's once-daily dosing (500mg) for suppression offers a compliance advantage over aciclovir's twice-daily regimen (400mg), though both are clinically effective when adherence is maintained.

Factors Affecting Treatment Response

Individual response to antiviral therapy varies based on immune status, outbreak severity, and treatment timing. Immunocompromised patients may require higher doses or longer treatment courses, as determined by a UK prescriber. Patients who consistently experience prolonged or severe outbreaks despite standard antiviral therapy should consult their GP or pharmacist for reassessment, as resistant HSV strains—though rare—can occasionally develop with repeated antiviral exposure [5].

Side Effects and Safety Profile Comparison

Both aciclovir and valaciclovir are generally well-tolerated, with similar safety profiles reflecting their shared active metabolite [2]. The most commonly reported side effects with oral aciclovir include headache (occurring in approximately 13% of patients), nausea, and diarrhoea [1]. These effects are typically mild and resolve without intervention.

Valaciclovir demonstrates a comparable adverse event profile, with headache and nausea being the most frequent complaints in clinical trials [4]. Because valaciclovir achieves higher peak plasma concentrations, adequate hydration is recommended during treatment to minimise the rare risk of crystalluria, particularly in patients with pre-existing renal impairment.

Topical aciclovir cream carries minimal systemic absorption and is associated primarily with localised reactions such as mild stinging, burning, or dryness at the application site [1]. Allergic contact dermatitis occurs rarely. Patients with known hypersensitivity to aciclovir, valaciclovir, or any excipients should avoid these medications and discuss alternative treatments with their prescriber.

Aciclovir vs Valaciclovir: Cost and Accessibility in the UK

Aciclovir has been available as a generic medication in the UK for decades, making it widely accessible at competitive pricing. Numark Cold Sore Cream (aciclovir 5%) is available from £4.49 at Cured Pharmacy without requiring a prescription, offering an affordable first-line option for mild recurrent cold sores.

Oral aciclovir and valaciclovir are prescription-only medications in the UK and require clinical assessment by a UK-registered prescriber before dispensing. At Cured Pharmacy, our free online consultation takes under three minutes and connects you with qualified UK prescribers who evaluate your suitability for treatment based on your medical history and outbreak characteristics.

When comparing overall treatment costs, valaciclovir's reduced dosing frequency may offset its typically higher per-tablet price for some patients. However, the clinical equivalence between properly dosed aciclovir and valaciclovir means cost considerations can be balanced against dosing convenience based on individual patient preference and lifestyle factors.

Prescription Requirements and Online Consultations

All prescription cold sore treatments at Cured Pharmacy are dispensed only after approval by our UK-registered clinical team. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical assessments to ensure patient safety and appropriate prescribing. Your consultation responses are reviewed by qualified prescribers who determine whether aciclovir, valaciclovir, or an alternative treatment is most suitable for your clinical presentation. Genuine UK-licensed medicines are dispensed from our GPhC-registered pharmacy (9012511) with 100% discreet packaging and next-day delivery options available.

Choosing Between Aciclovir and Valaciclovir: Clinical Recommendations

For patients experiencing infrequent, mild cold sores, topical aciclovir cream offers an accessible and cost-effective first-line treatment that can be initiated immediately at symptom onset. The convenience of over-the-counter availability makes it suitable for patients who recognise their prodromal symptoms early and prefer localised therapy.

Oral valaciclovir is particularly well-suited for patients requiring episodic treatment who value dosing convenience, those with moderate to severe outbreaks, or individuals needing suppressive therapy to reduce transmission risk in serodiscordant relationships. The simplified once or twice-daily dosing improves adherence and maintains therapeutic antiviral levels with less frequent administration.

Standard oral aciclovir remains an effective and economical option for patients who can maintain the five-times-daily dosing schedule and prefer a well-established generic medication. Your UK prescriber will consider your outbreak frequency, severity, medical history, concurrent medications, and personal preferences when recommending the most appropriate antiviral regimen during your clinical consultation.

Scientific References

1. Spruance, S. L., et al. (2002). Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrobial Agents and Chemotherapy, 46(7), 2238–2243. https://doi.org/10.1128/AAC.46.7.2238-2243.2002
2. Soul-Lawton, J., et al. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrobial Agents and Chemotherapy, 39(12), 2759–2764. https://doi.org/10.1128/AAC.39.12.2759
3. Spruance, S. L., et al. (1997). Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. Journal of Infectious Diseases, 175(5), 1138–1142. https://doi.org/10.1086/516452
4. Spruance, S. L., et al. (2003). Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. Journal of the American Academy of Dermatology, 49(3), 438–444. https://doi.org/10.1067/S0190-9622(03)00900-4
5. Rooney, J. F., et al. (1993). Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Annals of Internal Medicine, 118(4), 268–272. https://doi.org/10.7326/0003-4819-118-4-199302150-00004

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.